Exploring the effect of APOE ε4 on biomarkers of neurodegeneration in Alzheimer's disease.
Clin Chim Acta
; 562: 119876, 2024 Aug 15.
Article
de En
| MEDLINE
| ID: mdl-39025198
ABSTRACT
BACKGROUND AND AIMS:
This study aims to assess the association between APOE genotype and biomarkers of neurodegeneration in Alzheimer's disease (AD).METHODS:
We performed a retrospective observational study at the University Hospital "P. Giaccone" in Palermo, Italy. We enrolled patients with cognitive decline, including AD. For each patient, we measured amyloid beta (Aß)42, Aß40, tau protein phosphorylated at threonine 181 (pTau), total tau (tTau), neurogranin, alpha-synuclein, and neurofilament light chain (NfL) in cerebrospinal fluid (CSF).RESULTS:
The study population consisted of 194 patients (123 AD and 71 non-AD). AD patients have significantly lower Aß42 levels and Aß42/40 ratio and higher pTau, tTau, and NfLs levels than non-AD patients. In AD patients, the APOEε4 allele is associated with a significantly lower Aß42/40 ratio and higher levels of pTau, tTau, neurogranin, and alpha-synuclein. This association is not observed in non-AD patients.CONCLUSIONS:
This study provides evidence of the significant impact of the APOE ε4 allele on neurodegenerative biomarkers in AD patients, highlighting its role in exacerbating amyloid and tau pathology as well as synaptic degeneration.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Marqueurs biologiques
/
Apolipoprotéine E4
/
Maladie d'Alzheimer
Limites:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Langue:
En
Journal:
Clin Chim Acta
Année:
2024
Type de document:
Article
Pays d'affiliation:
Italie